Dashboard
Manage Tickers

ENLV


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
10/29/2025 11:03:15

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

enlivex-therapeutics-to-present-late-breaking-poster-at-acr-convergence-2025-featuring-phase-iia-topline-data-for-allocetra-in-patients-with-moderate-to-severe-knee-osteoarthritis-data-showed-clinically-meaningful-and-statistically-significant-improvements-in-pain-reduction-and-function-versus-placebo
Enlivex Therapeutics To Present Late-break...
10/28/2025 12:19:16

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy compa...

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
09/26/2025 11:29:00

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ: ENLV) with a Buy and maintains $13 price targ...

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
09/12/2025 12:00:33

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

enlivex-ceo-oren-hershkovitz-issues-shareholder-letter-highliting-phase-iia-topline-results-for-allocetra-in-knee-osteoarthritis-and-clinical-development-roadmap
Enlivex CEO Oren Hershkovitz Issues Shareh...
09/11/2025 12:11:19

Dear fellow shareholders,I would like to take this opportunity to provide you with our perspective on our recent Phase IIa (ENX...

enlivex-secures-israeli-patent-for-allocetra-in-osteoarthritis-treatment-extending-ip-protection-through-2040
Enlivex Secures Israeli Patent For Allocet...
09/09/2025 12:03:24

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy compa...

hc-wainwright--co-reiterates-buy-on-enlivex-therapeutics-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Enli...
09/02/2025 11:16:47

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7...

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
08/22/2025 11:03:34

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
08/18/2025 17:06:03

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
08/18/2025 12:43:10

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

trading-halt-halt-status-updated-at-80000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:00:...
08/18/2025 12:00:10

enlivex-drug-shows-relief-in-knee-osteoarthritis-trial-cutting-pain-by-72-for-some-patients
Enlivex Drug Shows Relief in Knee Osteoart...
08/18/2025 11:47:16

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Pa...

trading-halt-halted-at-74000-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:40:00 a.m. ET - ...
08/18/2025 11:40:05

enlivex-to-present-3-month-topline-data-from-phase-iia-stage-of-its-phase-iiia-enlx-cl-05-001-trial
Enlivex To Present 3-Month Topline Data Fr...
08/14/2025 12:43:07

Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patien...

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
07/29/2025 13:10:05

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
07/22/2025 12:14:25

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

enlivex-therapeutics-to-feature-data-from-ongoing-clinical-study-evaluating-proprietary-allocetra-off-the-shelf-macrophage-reprogramming-cell-therapy-in-patients-with-knee-osteoarthritis-at-eular-european-congress-of-rheumatology
Enlivex Therapeutics To Feature Data From ...
06/10/2025 12:34:30

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy compa...

enlivex-therapeutics-files-for-mixed-shelf-of-up-to-300m
Enlivex Therapeutics Files For Mixed Shelf...
05/02/2025 21:16:50

-SEC filing

d-boral-capital-maintains-buy-on-enlivex-therapeutics-maintains-13-price-target
D. Boral Capital Maintains Buy on Enlivex ...
04/21/2025 13:27:24

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.

enlivex-completes-patient-enrollment-in-phase-ii-stage-of-randomized-controlled-blinded-phase-iii-trial-of-allocetra-in-patients-with-moderate-to-severe-knee-osteoarthritis
Enlivex Completes Patient Enrollment In Ph...
04/21/2025 12:35:47

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clini...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION